SynAging Parkinson´s Solutions
SynAging has established a target validation and drug discovery platform for Parkinson´s disease that is based on its proprietary misfolded-α-synuclein-aggregate-induced disease models:
- human α-synuclein oligomers (aSO)
- human α-synuclein firbrils (aSF)
cause neurodegeneration in vitro and in vivo. SynAging's advantage is the highly reproducible creation of misfolded protein aggregates with entirely physicochemical methods and no use of crosslinkers, helper proteins, or other contaminants of the natural protein. Highly consistent neurotoxicity of the aggregates is achieved by the stable change of the 3D protein conformation and aggregation of the misfolded natural proteins, as is expected to happen in diseased patients.
To many drug discovery companies timing is of the essence. Therefore SynAging's services are optimized for fast performance and scalability of the experiments by using wilde type (WT) mice for the models, which are readily available and better represent the sporadic disease onset in patients. The timings for the α-synuclein oligomer and fibril induced models are indicated below.